Grant: P20GM109025) BD reports having received consultancy fees from Eli Lilly and Company and Boehringer-Ingelheim; and research funding for his Institution from Roche and Fondation Merck Avenir LF reports receiving honoraria or consultation fees from Avid-Eli Lilly and Company Schering-Plough, Schwabe Pharma, TAD Pharma, and Takeda; and receiving grants from Piramal and Novartis. CRJ reports having provided consulting services for Eli Lilly and Company; owning stock in Johnson and Johnson; and receiving research funding from the) and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation. RWJ reports honoraria and/or consultation fees from AC Immune Roche; and his Institute has received grants for clinical trials from AC Immune JCM reports that neither he nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company; reports participating in the execution of trials of antidementia drugs from Eli Lilly and Company, Biogen, and Janssen; reports serving as a consultant for Eli Lilly and Company; reports receiving research support from Eli Lilly/Avid Radiopharmaceuticals; and reports receiving funding by NIH grants, Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests PSA reports beingP50AG005681; P01AG003991; P01AG026276, and UF01AG032438). RS reports receiving research funding from the National Institute on Aging, the Alzheimer's Association, Fidelity Biosciences, and several philanthropic organizations, Eli Lilly and Co., and Janssen Pharmaceuticals; and has served as a paid consultant to Abbvie Sanofi. SAD, BRM, and JR report being full-time employees and minor stockholders of Eli Lilly and Company. PS reports having acquired grant support from GE Healthcare, Danone Research, Piramal, and MERCK; having received in the past 2 years consultancy/speaker fees (paid to the institution) from Eli Lilly and Company, 11378. ,
The Netherlands. 11 Institute for Memory and Alzheimer's Disease (IM2A) and ICM ,
A hundred years of Alzheimer's disease research, Neuron, vol.52, pp.3-13, 2006. ,
The Nature and Pathogenesis of the Amyloid Deposits in Alzheimer???s Disease, Appl Pathol, vol.2, pp.357-69, 1984. ,
DOI : 10.1007/978-94-009-4309-4_24
Mise en evidence de la immunologique de la protein tau au lesions de degeneresescence neurofibrillaire de la maladie, Arch Biol (Brux), vol.95, pp.229-264, 1985. ,
Drug development in Alzheimer???s disease: the path to 2025, Alzheimer's Research & Therapy, vol.22, issue.1, pp.10-1186, 2016. ,
DOI : 10.1016/j.jalz.2016.04.008
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics, Science, vol.297, issue.5580, pp.353-359, 2002. ,
DOI : 10.1126/science.1072994
Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease, Neurobiology of Aging, vol.30, issue.7, pp.1026-1062, 2009. ,
DOI : 10.1016/j.neurobiolaging.2009.04.002
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study, The Lancet Neurology, vol.12, issue.10, pp.957-65, 2013. ,
DOI : 10.1016/S1474-4422(13)70194-7
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904678
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathologica, vol.80, issue.4, pp.239-59, 1991. ,
DOI : 10.1007/978-3-642-70644-8_2
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease, Annals of Neurology, vol.46, issue.suppl, pp.17-24, 1997. ,
DOI : 10.1002/ana.410300206
The Cellular Phase of Alzheimer???s Disease, Cell, vol.164, issue.4, pp.603-618, 2016. ,
DOI : 10.1016/j.cell.2015.12.056
Neurobiology of Alzheimer???s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions, Current Alzheimer Research, vol.12, issue.8, pp.712-734, 2015. ,
DOI : 10.2174/1567205012666150701103107
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384474
Amyloid-?? and tau ??? a toxic pas de deux in Alzheimer's disease, Nature Reviews Neuroscience, vol.37, issue.2, pp.65-72, 2011. ,
DOI : 10.1016/j.nbd.2009.09.004
Tau and tauopathies, Brain Research Bulletin, vol.126, pp.238-92, 2016. ,
DOI : 10.1016/j.brainresbull.2016.08.018
Primary age-related tauopathy (PART): a common pathology associated with human aging, Acta Neuropathologica, vol.35, issue.Suppl 2, pp.755-66, 2014. ,
DOI : 10.1016/j.neurobiolaging.2013.10.074
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257842
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease, Acta Neuropathologica, vol.23, issue.Suppl 2, pp.757-62, 2015. ,
DOI : 10.1046/j.1440-1789.2003.00522.x
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4534004
Toward defining the preclinical stages of Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.280-92, 2011. ,
DOI : 10.1016/j.jalz.2011.03.003
Amyloid and APOE ??4 interact to influence short-term decline in preclinical Alzheimer disease, Neurology, vol.82, issue.20, pp.1760-1767, 2014. ,
DOI : 10.1212/WNL.0000000000000431
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035706
Cognitive reserve in ageing and Alzheimer's disease, The Lancet Neurology, vol.11, issue.11, pp.1006-1018, 2012. ,
DOI : 10.1016/S1474-4422(12)70191-6
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, The Lancet, vol.385, issue.9984, pp.2255-63, 2015. ,
DOI : 10.1016/S0140-6736(15)60461-5
Heavy Smoking in Midlife and Long-term Risk of Alzheimer Disease and Vascular Dementia, Archives of Internal Medicine, vol.171, issue.4, pp.333-342, 2011. ,
DOI : 10.1001/archinternmed.2010.393
Advances in the prevention of Alzheimer's disease and dementia, Journal of Internal Medicine, vol.293, issue.Suppl. 3, pp.229-50, 2014. ,
DOI : 10.1001/jama.293.18.2257
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, The Lancet Neurology, vol.13, issue.6, pp.614-29757, 2014. ,
DOI : 10.1016/S1474-4422(14)70090-0
Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease, Brain, vol.133, pp.3336-3384, 2010. ,
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers, Lancet Neurol, vol.12, pp.207-223, 2013. ,
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease, New England Journal of Medicine, vol.367, issue.9, pp.795-804, 2012. ,
DOI : 10.1056/NEJMoa1202753
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474597
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.53, issue.3, pp.4502-4511, 2013. ,
DOI : 10.2307/2533558
Associations Between Biomarkers and Age in the Presenilin 1 E280A Autosomal Dominant Alzheimer Disease Kindred, JAMA Neurology, vol.72, issue.3, pp.316-340, 2015. ,
DOI : 10.1001/jamaneurol.2014.3314
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease, J Alzheimers Dis, vol.29, pp.319-346, 2012. ,
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer???s disease, Brain, vol.139, issue.5, pp.1551-67, 2016. ,
DOI : 10.1093/brain/aww027
URL : http://doi.org/10.1093/brain/aww027
Amyloid ?? deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study, The Lancet Neurology, vol.12, issue.4, pp.357-67, 2013. ,
DOI : 10.1016/S1474-4422(13)70044-9
Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease, Human Brain Mapping, vol.41, issue.11, pp.4421-4458, 2015. ,
DOI : 10.1016/j.neuron.2012.03.004
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia, JAMA, vol.313, issue.19, pp.1924-1962, 2015. ,
DOI : 10.1001/jama.2015.4668
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families, Science, vol.261, issue.5123, pp.921-924, 1993. ,
DOI : 10.1126/science.8346443
Apolipoprotein E, ??4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region, Human Molecular Genetics, vol.3, issue.4, pp.569-74, 1994. ,
DOI : 10.1093/hmg/3.4.569
Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community, JAMA Neurology, vol.73, issue.1, pp.85-92481, 2016. ,
DOI : 10.1001/jamaneurol.2015.3098
Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease, Archives of Neurology, vol.66, issue.10, pp.1254-1263, 2009. ,
DOI : 10.1001/archneurol.2009.158
The Preclinical Alzheimer Cognitive Composite, JAMA Neurology, vol.71, issue.8, pp.961-70, 2014. ,
DOI : 10.1001/jamaneurol.2014.803
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439182
Subjective and objective cognitive decline at the pre-dementia stage of Alzheimer???s disease, European Archives of Psychiatry and Clinical Neuroscience, vol.9, issue.S1, pp.3-7, 2014. ,
DOI : 10.1371/journal.pone.0100812
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer???s Disease, Journal of Alzheimer's Disease, vol.61, issue.1, pp.205-219, 2015. ,
DOI : 10.1001/archneur.61.4.556
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-780, 2007. ,
DOI : 10.1016/S1474-4422(07)70178-3
The diagnosis of mild cognitive impairment due to Alzheimer???s disease: Recommendations from the National Institute on Aging-Alzheimer???s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, vol.7, issue.3, pp.270-279, 2011. ,
DOI : 10.1016/j.jalz.2011.03.008
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Synergistic effect of ?-amyloid and neurodegeneration on cognitive decline in clinically normal individuals, JAMA Neurol, vol.71, pp.1379-85, 2014. ,
Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, vol.78, issue.6, pp.379-86, 2012. ,
DOI : 10.1212/WNL.0b013e318245f447
Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review, Alzheimer's Research & Therapy, vol.8, issue.Suppl 2, p.17, 2015. ,
DOI : 10.2147/CIA.S40087
An unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, vol.87, pp.539-586, 2016. ,
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria, Alzheimer's & Dementia, vol.12, issue.3, pp.292-323, 2015. ,
DOI : 10.1016/j.jalz.2016.02.002
Cerebrospinal Fluid Biomarkers for Alzheimer???s Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team, Journal of Alzheimer's Disease, vol.7, issue.Suppl, pp.19-35, 2017. ,
DOI : 10.3233/JAD-160573
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease, NeuroImage: Clinical, vol.2, pp.356-65, 2013. ,
DOI : 10.1016/j.nicl.2013.02.006
Tau positron emission tomographic imaging in aging and early Alzheimer disease, Annals of Neurology, vol.128, issue.3 pt 1, pp.110-119, 2016. ,
DOI : 10.1007/s00401-014-1349-0
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738026
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, Alzheimer's & Dementia, vol.12, issue.2, pp.110-130, 2016. ,
DOI : 10.1016/j.jalz.2015.06.1893
URL : http://doi.org/10.1016/j.jalz.2015.06.1893
Mild cognitive impairment due to Alzheimer disease in the community, Ann Neurol, vol.74, pp.199-208, 2013. ,
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's disease Cooperative Study Alzheimer's Disease and Associated Disorders, pp.33-42, 1997. ,
The trajectory of cognitive decline in the pre-dementia phase in memory clinic visitors: findings from the 4C-MCI study, Psychological Medicine, vol.34, issue.07, pp.1509-1528, 2015. ,
DOI : 10.1016/S1474-4422(06)70550-6
ADCS Prevention Instrument Project: The Mail-In Cognitive Function Screening Instrument (MCFSI), Alzheimer Disease & Associated Disorders, vol.20, issue.Supplement 3, pp.170-178, 2006. ,
DOI : 10.1097/01.wad.0000213879.55547.57
Assessing Financial Capacity in Patients With Alzheimer Disease, Archives of Neurology, vol.57, issue.6, pp.877-84, 2000. ,
DOI : 10.1001/archneur.57.6.877
Lipton RB Screening for dementia with the Memory Impairment Screen H, Neurology, vol.52, 1999. ,
Genuine memory deficits in dementia, Developmental Neuropsychology, vol.8, issue.1, pp.13-36, 1987. ,
DOI : 10.1080/01688638308401157
The AD8: A brief informant interview to detect dementia, Neurology, vol.65, issue.4, pp.559-64, 2005. ,
DOI : 10.1212/01.wnl.0000172958.95282.2a
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials, Journal of Neurology, Neurosurgery & Psychiatry, vol.2, issue.9, pp.993-1002, 2016. ,
DOI : 10.1001/archneur.64.9.1323
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013117
The GPCOG: A New Screening Test for Dementia Designed for General Practice, Journal of the American Geriatrics Society, vol.44, issue.3, pp.530-534, 2002. ,
DOI : 10.1093/geront/9.3_Part_1.179
The Mini-Cog: a cognitive ?vital signs? measure for dementia screening in multi-lingual elderly, International Journal of Geriatric Psychiatry, vol.12, issue.11, pp.1021-1028, 2000. ,
DOI : 10.1002/(SICI)1099-1166(199701)12:1<101::AID-GPS469>3.0.CO;2-R
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity, Journal of Clinical and Experimental Neuropsychology (Neuropsychology, Development and Cognition: Section A), vol.20, issue.3, pp.310-319, 1988. ,
DOI : 10.1076/jcen.20.3.310.823
The " 5-words " : a simple and sensitive test for the diagnosis of Alzheimer's disease, Presse Med, vol.31, pp.1696-1705, 2002. ,
Validity of the Five-Word Test for the Evaluation of Verbal Episodic Memory and Dementia in a Memory Clinic Setting, Journal of Geriatric Psychiatry and Neurology, vol.163, issue.3, pp.78-84, 2012. ,
DOI : 10.1016/S0035-3787(07)90404-X
The California Verbal Learning Test: Psychometric characteristics and clinical application, Neuropsychology Review, vol.99, issue.Suppl., pp.173-201, 1995. ,
DOI : 10.1176/ajp.152.1.137
The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment, Journal of the American Geriatrics Society, vol.48, issue.4, pp.695-704, 2005. ,
DOI : 10.1212/WNL.52.2.231
Addenbrooke???s Cognitive Examination-III, Occupational Medicine, vol.65, issue.5, pp.418-438, 2015. ,
DOI : 10.1093/occmed/kqv041
???Mini-mental state???, Journal of Psychiatric Research, vol.12, issue.3, pp.189-98, 1975. ,
DOI : 10.1016/0022-3956(75)90026-6
A new rating scale for Alzheimer's disease, Am J Psychiatry, vol.41, pp.1356-64, 1984. ,
Clinical Dementia Rating (CDR) Psychopharm Bull, pp.637-646, 1988. ,
Neuropsychological assessment of the severely impaired elderly patient, Clin Geriatr Med, vol.5, pp.531-574, 1989. ,